Short answer
Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on November 20, 2026 reporting Item 8.01 (Other Events). ERAS-0015 showed confirmed ORR of 44% in 2L+ KRAS G12X PDAC, including 69% for KRAS G12D/G12V tumors.
Erasca, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- ERAS-0015 showed confirmed ORR of 44% in 2L+ KRAS G12X PDAC, including 69% for KRAS G12D/G12V tumors
- Additional activity in NSCLC, 58% ORR across 16-32 mg QD, and BTC, 75% ORR at 32 mg QD
- Safety remained manageable at 32 mg QD, with 0% discontinuations and 16.7% dose reductions, but one prior Grade 5 pneumonitis death
- Phase 3 1L pancreatic cancer trial accelerated to the first half of 2027, materially increasing near-term execution and funding needs
- ERAS-4001 showed favorable preliminary safety and activity, supporting a planned 2027 combination trial with ERAS-0015
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Erasca, Inc. 8-K filings
Get the next ERAS 8-K as it lands
Follow ERAS for push alerts, or ask the research agent what this filing means.